BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29507047)

  • 1. Immune landscape of papillary thyroid cancer and immunotherapeutic implications.
    Na KJ; Choi H
    Endocr Relat Cancer; 2018 May; 25(5):523-531. PubMed ID: 29507047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Landscape of Thyroid Cancers: New Insights.
    Menicali E; Guzzetti M; Morelli S; Moretti S; Puxeddu E
    Front Endocrinol (Lausanne); 2020; 11():637826. PubMed ID: 33986723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer.
    Niederer-Wüst SM; Jochum W; Förbs D; Brändle M; Bilz S; Clerici T; Oettli R; Müller J; Haile SR; Ess S; Stoeckli SJ; Broglie MA
    Surgery; 2015 Jan; 157(1):119-25. PubMed ID: 25482468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
    Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive gene expression analysis for exploring the association between glucose metabolism and differentiation of thyroid cancer.
    Suh HY; Choi H; Paeng JC; Cheon GJ; Chung JK; Kang KW
    BMC Cancer; 2019 Dec; 19(1):1260. PubMed ID: 31888560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.
    Guerra A; Fugazzola L; Marotta V; Cirillo M; Rossi S; Cirello V; Forno I; Moccia T; Budillon A; Vitale M
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2333-40. PubMed ID: 22508706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related.
    Bai Y; Guo T; Huang X; Wu Q; Niu D; Ji X; Feng Q; Li Z; Kakudo K
    Virchows Arch; 2018 May; 472(5):779-787. PubMed ID: 29651624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the BRAF V600E Mutation: A Single-Institution Study.
    Kowalska A; Walczyk A; Kowalik A; Pałyga I; Trybek T; Kopczyński J; Kajor M; Chrapek M; Pięciak L; Chłopek M; Góźdź S; Kamiński G
    Thyroid; 2016 Apr; 26(4):543-51. PubMed ID: 26889698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic Characteristics, Natural History, and Prognostic Implications of BRAF
    Hardee S; Prasad ML; Hui P; Dinauer CA; Morotti RA
    Pediatr Dev Pathol; 2017 Jun; 20(3):206-212. PubMed ID: 28521635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of the extent of BRAF
    Liu L; Chang JW; Jung SN; Park HS; Oh T; Lim YC; Koo BS
    Oral Oncol; 2016 Nov; 62():72-77. PubMed ID: 27865374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center.
    Lim JY; Hong SW; Lee YS; Kim BW; Park CS; Chang HS; Cho JY
    Thyroid; 2013 Nov; 23(11):1423-30. PubMed ID: 23496275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
    Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between BRAF
    Geng J; Wang H; Liu Y; Tai J; Jin Y; Zhang J; He L; Fu L; Qin H; Song Y; Su J; Zhang A; Wen X; Guo Y; Ni X
    Sci China Life Sci; 2017 Jul; 60(7):729-738. PubMed ID: 28646474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to therapy of papillary thyroid cancer of known BRAF status.
    Kowalska A; Walczyk A; Kowalik A; Pałyga I; Gąsior-Perczak D; Trybek T; Kopczyński J; Kajor M; Mikina E; Szymonek M; Gadawska-Juszczyk K; Szyska-Skrobot D; Lizis-Kolus K; Hurej S; Chrapek M; Chłopek M; Góźdź S
    Clin Endocrinol (Oxf); 2017 Dec; 87(6):815-824. PubMed ID: 28718951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment.
    Xie Z; Li X; He Y; Wu S; Wang S; Sun J; He Y; Lun Y; Zhang J
    Front Endocrinol (Lausanne); 2020; 11():570604. PubMed ID: 33193087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
    Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer.
    Kim SJ; Myong JP; Jee HG; Chai YJ; Choi JY; Min HS; Lee KE; Youn YK
    Head Neck; 2016 Jan; 38(1):95-101. PubMed ID: 25213729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.